---
title: A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.
euct_id: 2024-511110-21-00
phase: Phase 1
status: Recruiting
sponsor: F. Hoffmann-La Roche AG
canonical_url: "https://parkinsonspathways.com/trials/eu/2024-511110-21-00"
eu_clinical_trials_register: "https://euclinicaltrials.eu/ctis-public/view/2024-511110-21-00"
ctis_last_updated: "2026-03-27T02:41:48.050945289"
source: EU Clinical Trials Information System (CTIS)
---
# A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.

**EU CT Number:** [2024-511110-21-00](https://euclinicaltrials.eu/ctis-public/view/2024-511110-21-00)

## Key Facts

- **Phase:** Phase 1
- **Status:** Recruiting
- **Sponsor:** F. Hoffmann-La Roche AG
- **Start Date:** 2024-10-02
- **Completion Date:** 2028-04-11
- **Conditions:** Parkinson’s Disease, Parkinson's disease

## Member States

Trial is authorized in 1 member state: Netherlands.

## Sites (5)

- Radboud universitair medisch centrum Stichting, Nijmegen, Netherlands
- Pharmaceutical Research Associates Group B.V., Groningen, Netherlands
- Brain Research Center Zwolle B.V., Zwolle, Netherlands
- Brain Research Center Amsterdam B.V., Amsterdam, Netherlands
- Brain Research Center Den Bosch B.V., 's-Hertogenbosch, Netherlands

## Eligibility (CTIS)

- **Minimum age:** 18 Years
- **Sex:** ALL

```
Condition: Parkinson’s Disease; Parkinson's disease
Age groups: elderly 65+, adults 18-64
Sex: male, female
Includes a vulnerable population.
```

---

*Canonical: https://parkinsonspathways.com/trials/eu/2024-511110-21-00*  
*HTML version: https://parkinsonspathways.com/trials/eu/2024-511110-21-00*  
*Source data: https://euclinicaltrials.eu/ctis-public/view/2024-511110-21-00*